证券代码：688177 证券简称：百奥泰 公告编号：2026-003 百奥泰生物制药股份有限公司 关于全资子公司与关联方签订建设工程施工合同 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易内容：百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"） 全资子公司百奥泰生物药业（广州）有限公司（以下简称"百奥泰药业"）拟与 公司关联方潜江市水牛建筑工程有限公司（以下简称"水牛建筑"）就百奥泰永 和创新产业基地签订《建设工程施工合同》，合同价格为人民币 85,562,617.34 元（以下简称"本次关联交易"），本次关联交易属于公司正常生产经营活动。 水牛建筑为百奥泰实际控制人控制的企业，本次交易构成关联交易，但 不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 本次交易实施不存在重大法律障碍。 本次关联交易已经公司第三届董事会第六次会议、第三届董事会审计委 员会及第三届董事会独立董事第二次专门会议审议通过，尚需提交公司股东会 审议。 一、关联交易概述 公司全资子公司百奥泰药 ...

百奥泰生物制药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 证券代码：688177 证券简称：百奥泰 公告编号：2026-004 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 2 月 6 日 14 点 00 分 召开地点：广州市国际生物岛螺旋二路 18 号百奥泰创新中心一楼展厅 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 6 日 至2026 年 2 月 6 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年2月6日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） ...

格隆汇1月21日丨百奥泰(688177.SH)公布，公司全资子公司百奥泰药业拟与水牛建筑就百奥泰永和创新 产业基地的建设施工服务及有关事项签署《建设工程施工合同》，本次定价根据第三方工程造价预算为 基础，合同价格为人民币8556.26万元。 ...

格隆汇1月21日丨百奥泰(688177.SH)公布，公司全资子公司百奥泰药业拟与水牛建筑就百奥泰永和创新 产业基地的建设施工服务及有关事项签署《建设工程施工合同》，本次定价根据第三方工程造价预算为 基础，合同价格为人民币8556.26万元。 ...

百奥泰公告称，其全资子公司百奥泰药业拟与关联方水牛建筑就百奥泰永和创新产业基地签订《建设工 程施工合同》，合同价8556.26万元。水牛建筑由公司实控人控制，本次交易构成关联交易，但不构成 重大资产重组。水牛建筑2024 - 2025年营收分别为1.92亿元、1.06亿元，净利润分别为162.90万元、 139.93万元。该议案已通过董事会相关会议审议，尚需股东会审议。 ...

Group 1 - The core viewpoint of the news is that Baiotai's stock price has shown fluctuations, with a current price of 25.24 CNY per share and a market capitalization of 10.451 billion CNY [1] - Baiotai's stock has increased by 9.08% since the beginning of the year, with a 2.60% rise in the last five trading days and a 9.93% increase over the last 20 days, while it has decreased by 5.64% over the last 60 days [2] - The company, established on July 28, 2003, focuses on the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2] Group 2 - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a year-on-year increase of 38.72% [2] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is involved in concepts such as biomedicine and innovative drugs [2] - As of September 30, 2025, the number of shareholders decreased by 0.89% to 9,397, with an average of 44,065 circulating shares per person, which increased by 0.89% [2]

Group 1 - The company received a milestone payment of $2.5 million from Gedeon Richter Plc [1] - The BAT2206 (Ustinumab) injection has been approved by the FDA and EMA, with a submission for approval to the National Medical Products Administration currently under review [1] - On October 8, 2024, the company signed a licensing, production, supply, and commercialization agreement with Gedeon Richter for BAT2206, granting exclusive commercialization rights in the EU, UK, and other countries [1] Group 2 - The total amount of upfront and milestone payments could reach up to $110 million, including an upfront payment of $8.5 million and milestone payments not exceeding $101.5 million [1] - The agreement includes a revenue-sharing model based on a double-digit percentage of net sales [1]

根据协议约定，百奥泰于近日收到由吉瑞医药一次性支付的 250 万美元里程 碑付款（实际到账金额须扣除银行手续费）。该笔款项的到账，进一步充盈了公 司的现金储备，也为公司后续管线研发和国际化战略的推进提供助力。 截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监 督管理局（FDA）和欧洲药品管理局（EMA）批准上市，美国注册商品名 为 STARJEMZA®，欧洲注册商品名为 Usymro ®；已向国家药品监督管理局 （NMPA）提交上市申请，目前正在评审中。 协议履行的风险详见公司于 2024 年 10 月 9 日披露的《百奥泰生物制药股份 有限公司关于与 Gedeon Richter Plc.（吉瑞医药）就 BAT2206（乌司奴单抗）注 射液签署授权许可及生产、供货和商业化协议的公告》（公告编号：2024-051） 之"五、协议履行的风险分析"。 敬请广大投资者注意投资风险，公司将严格按照有关规定及时对本协议后续 进展情况履行信息披露义务。 证券代码：688177 证券简称：百奥泰 公告编号：2026-002 百奥泰生物制药股份有限公司 自愿披露关于与 Gedeon Richter Pl ...

Core Viewpoint - The company has approved a licensing and commercialization agreement for BAT2206, receiving a milestone payment of $2.5 million from Jireh Pharmaceuticals, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The company received a one-time milestone payment of $2.5 million, which strengthens its cash reserves [1] - The payment is expected to assist in the advancement of the company's pipeline research and international strategy [1] Group 2: Product Development - BAT2206 injection has been approved for market by the U.S. FDA and the European Medicines Agency, with the U.S. brand name STARJEMZA® and the European brand name Usymro® [1] - The company has submitted a marketing application to the National Medical Products Administration, which is currently under review [1]

Core Insights - Approximately 130 A-share companies have disclosed their performance forecasts for 2025, with around 70 companies expecting positive results, including profit increases and turnaround from losses [2][4]. Company Performance Highlights - **Zhongke Lanyun**: Expected net profit of 1.4 billion to 1.43 billion yuan, a year-on-year increase of 366.51% to 376.51%, driven by strategic investments in high-growth areas like GPU and advanced packaging [4][5]. - **Chuanhua Zhili**: Forecasted net profit of 540 million to 700 million yuan, with a growth rate of 256.07% to 361.57%, supported by optimized marketing strategies and asset structure in logistics and chemical businesses [5]. - **Bai'ao Saitou**: Anticipated net profit of 135 million yuan, reflecting a 303.57% increase, attributed to favorable market conditions [4]. - **Kangchen Pharmaceutical**: Expected net profit of 145 million to 175 million yuan, with a growth of 243% to 315%, due to the absence of goodwill impairment losses in the reporting period [5]. - **Guangku Technology**: Projected net profit of 169 million to 182 million yuan, a growth of 152% to 172%, driven by product innovation and cost control [7]. - **Lixun Precision**: Forecasted net profit of 16.518 billion to 17.186 billion yuan, with a growth of 23.59% to 28.59%, supported by innovations in manufacturing and AI integration [6]. - **Daotong Technology**: Expected net profit of 900 million to 930 million yuan, with a growth of 40.42% to 45.10%, driven by AI-driven services [6]. - **Aibisen**: Anticipated net profit of 240 million to 290 million yuan, reflecting a growth of 105.32% to 148.09%, due to increased R&D investment [7]. - **Chaohongji**: Expected net profit of 436 million to 533 million yuan, with a growth of 125% to 175%, supported by a focus on brand optimization and digital transformation [9]. - **WuXi AppTec**: Forecasted net profit of 19.151 billion yuan, with a growth of approximately 102.65%, including gains from divesting joint ventures [9]. - **Hui Sheng Biological**: Expected net profit of 23.5 million to 27.1 million yuan, indicating a turnaround, driven by market expansion and improved production efficiency [9]. Industry Performance Insights - The electronics, semiconductor, pharmaceutical, and machinery sectors are showing strong performance among listed companies [3].